NCT05734339View on ClinicalTrials.gov

Patient-Reported Outcomes of Benralizumab in Real-World Use in Severe Eosinophilic Asthma Patients in Taiwan (BEAT)

CompletedOBSERVATIONAL
Enrollment

43

Participants

Timeline

Start Date

January 19, 2023

Primary Completion Date

February 3, 2025

Study Completion Date

February 3, 2025

Conditions
Asthma
Trial Locations (6)

Unknown

Research Site, Changhua

Research Site, Kaohsiung City

Research Site, New Taipei City

Research Site, Tainan City

Research Site, Taipei

Research Site, Taoyuan

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT05734339 - Patient-Reported Outcomes of Benralizumab in Real-World Use in Severe Eosinophilic Asthma Patients in Taiwan (BEAT) | Biotech Hunter | Biotech Hunter